13F Holdings
中文EN

SVRA Savara Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1160308 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.1%
TTM EPS YoY-13.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-151.0%
ROA-102.9%
ROIC (approx.)-114.7%
Asset turnover—

Leverage & solvency

Liabilities / assets30.8%
Debt / equity0.28x
Current ratio8.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-15.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$81.40M$78.03M$44.26M$27.88M$28.99M
SG&A expense$42.06M$25.04M$15.67M$10.93M$12.35M
Operating income-$123.55M-$103.20M-$60.01M-$38.84M-$41.48M
Pretax income-$118.84M-$95.88M-$54.70M-$38.15M-$43.01M
Income tax$0$9,000———
Net income-$118.84M-$95.88M-$54.70M-$38.15M-$43.01M
EBITDA-$123.46M-$103.07M-$59.93M-$38.81M-$41.34M
EPS (basic)-0.53-0.48-0.33-0.25-0.32
EPS (diluted)-0.53-0.48-0.33-0.25-0.32
Weighted avg. shares (diluted)222.39M198.19M165.20M152.77M133.92M
Balance sheet
Cash & equivalents$33.18M$15.13M$26.59M$52.10M$34.01M
Short-term investments$202.52M$181.20M$135.73M$73.78M$127.16M
Current assets$241.62M$202.13M$165.95M$128.95M$165.00M
PP&E, net$100,000$165,000$270,000$51,000$73,000
Total assets$253.44M$212.88M$177.56M$139.78M$176.60M
Current liabilities$20.40M$14.72M$10.60M$5.87M$14.66M
Short-term debt$0$0——$8.33M
Long-term debt$29.91M$26.62M$26.35M$26.08M$17.32M
Total debt$29.91M$26.62M$26.35M$26.08M$25.66M
Total liabilities$50.30M$41.43M$37.19M$32.00M$32.10M
Shareholders' equity$203.13M$171.45M$140.37M$107.78M$144.50M
Net debt-$3.27M$11.49M-$237,000-$26.02M-$8.36M
Shares outstanding204.57M172.42M138.14M114.05M114.04M
Cash flow statement
Operating cash flow-$101.04M-$89.09M-$51.06M-$34.55M-$40.08M
Capital expenditure$22,000$25,000$296,000$9,000$57,000
Free cash flow-$101.06M-$89.11M-$51.36M-$34.56M-$40.14M
Investing cash flow-$18.44M-$39.94M-$57.12M$52.65M-$69.46M
Financing cash flow$137.81M$117.58M$82.78M$87,000$120.81M
Depreciation & amortization$87,000$130,000$77,000$31,000$136,000
Stock-based compensation$14.42M$9.86M$4.18M$2.04M$3.26M

Free plan shows the latest 5 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.